Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Moderate Buy” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $19.6667.

A number of research analysts have recently issued reports on the stock. BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Tvardi Therapeutics in a research report on Tuesday, July 7th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research note on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday. Finally, HC Wainwright assumed coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price target for the company.

Tvardi Therapeutics Stock Performance

Shares of TVRD traded down $0.52 during mid-day trading on Friday, reaching $3.28. 2,756,722 shares of the company were exchanged, compared to its average volume of 6,259,464. Tvardi Therapeutics has a 52 week low of $1.50 and a 52 week high of $43.65. The stock has a market capitalization of $30.77 million, a PE ratio of -1.06 and a beta of 0.39. The business has a 50 day simple moving average of $3.10 and a two-hundred day simple moving average of $3.53.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). On average, analysts predict that Tvardi Therapeutics will post -2.32 EPS for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after purchasing an additional 20,757 shares in the last quarter. American Financial Group Inc. acquired a new stake in shares of Tvardi Therapeutics during the 4th quarter worth approximately $962,000. Vestal Point Capital LP acquired a new stake in shares of Tvardi Therapeutics during the 3rd quarter worth approximately $6,508,000. Geode Capital Management LLC lifted its position in shares of Tvardi Therapeutics by 6.2% during the 4th quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after acquiring an additional 9,214 shares during the period. Finally, State Street Corp boosted its stake in Tvardi Therapeutics by 83.7% during the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock worth $497,000 after acquiring an additional 52,637 shares in the last quarter. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.